Rosemont expands liquid medicine portfolio with Lucis acquisition
Rosemont is targeting the single-use sachet market, shaping its decision to acquire Lucis and its pipeline products.
Oral liquid medicine manufacturer Rosemont Pharmaceuticals has announced the acquisition of Lucis Pharma.
UK-based Rosemont hopes that this latest acquisition will bolster its portfolio with a pipeline of innovative products and allow it to serve the UK and overseas markets.
Rosemont believes this acquisition will allow it to enter the single-use sachet pharmaceutical market, expanding its liquid medicines portfolio in a growing market. In a June statement, Rosemont CEO Howard Taylor highlighted Lucis’ product pipelines and developer relationships as a driver of the acquisition, accelerating Rosemont’s entry into the sachet market.
A Rosemont spokesperson affirmed the company’s enthusiasm for the market, telling Pharmaceutical Technology that single-use sachets offer a greater level of convenience for current and potential patients. The manufacturer also disclosed that it is seeking further acquisitions in this space.
Founded in 2012, Lucis develops and licenses novel and exclusive medicines. It currently offers more than a dozen products across a range of therapeutic areas, with a pipeline of liquid medicines proving particularly attractive to Rosemont.
These offerings will complement over 130 oral liquid medicines currently offered by Rosemont to meet the needs of dysphagic patients.
The company also offers over 50 years of experience in novel, oral liquid medicines. It manufactures over one million litres of bulk liquid annually, equating to four million bottles of liquid medicine.
Liquid medicines are an important avenue of treatment for patients with swallowing difficulties or dysphagia. Most nursing home residents and stroke patients experience dysphagia to some extent. Patients with Parkinson’s disease are particularly affected, together with those with intellectual disabilities. Children are also heavily affected, with 25%-45% of paediatric patients experiencing dysphagia.
According to a GlobalData epidemiology forecast, there will be nearly 190 million cases of dysphagia globally by 2030. China will comprise a majority at almost 120 million cases, followed by India at 35 million. While the markets there are generally well served by local manufacturers, Rosemont plans to establish distribution centres in the Greater Bay Area of China to fill gaps in the market.
GlobalData is the parent company of Pharmaceutical Technology.
What's Your Reaction?
